Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.
The user switched from finasteride to dutasteride and is using minoxidil and RU58841 for hair loss treatment. They are satisfied with the progress and considering a hair transplant, despite some initial shedding after the medication change.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
Low-level laser therapy hats for hair loss, with skepticism about their effectiveness and cost. Users suggest trying affordable alternatives instead of expensive options.
People discussed which is better for hair loss treatment between a dermaroller and a dermastamp, concluding that a dermastamp is better. They also mentioned that a dermaroller can be used for beard growth.
A 40-year-old man shared a 9-month update on his hair loss treatment, which includes 1.25mg finasteride, 8% minoxidil, RU58841, dermarolling, ketoconazole shampoo, and vitamins, with no significant side effects. He has seen improvement in his hair growth and has stopped wearing hats as a result.
The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.
The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.
Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.